Big Pharma is rich. So much so, their coffers could buy more than 600 biotechs
The pandemic made Big Pharma even richer than before as vaccines and therapeutics splashed onto the market to the tune of billions of dollars. In the sophomore year of the pandemic, a boom in biotech interest fueled a rise in VC funding and a preclinical IPO flurry.
But the startup world was hit hard, as many early-stage biotechs have faltered and faced an unrelenting bear market in recent quarters.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.